NGNE (Neurogene) Marketable Securities : $175.82 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Neurogene's Marketable Securities for the quarter that ended in Dec. 2024 was $175.82 Mil.

Neurogene's annual Marketable Securities increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($48.95 Mil) and increased from Dec. 2023 ($48.95 Mil) to Dec. 2024 ($175.82 Mil).

Neurogene Marketable Securities Historical Data

The historical data trend for Neurogene's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Marketable Securities Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Marketable Securities

48.95

175.82

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Marketable Securities	Get a 7-Day Free Trial						48.95	19.39	42.87	72.36	175.82

Neurogene Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Neurogene (NAS:NGNE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Neurogene Marketable Securities Related Terms

Thank you for viewing the detailed overview of Neurogene's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

UU8:Germany

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.